Clinical trial
Keratinocyte Growth Factor to Prevent Acute GVHD
NCT00031148 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00031148 |
|---|---|
| Title | Keratinocyte Growth Factor to Prevent Acute GVHD |
| Official title | Phase I/II Trial of Keratinocyte Growth Factor (rHuKGF) to Prevent Acute GVHD in 6/6 HLA=BMT Recipients |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft-vs-Host Disease |
| Intervention type | Drug |
| Interventions | Recombinant Human Keratinocyte Growth Factor (rHuKGF) |
| Enrollment | 72 |
| Start date | Sep 1, 2001 |
| Completion | Aug 1, 2003 |
| First posted | Feb 27, 2002 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: